国际应激性溃疡预防试验中的知情同意:模式与预测因素
该研究在国际随机试验(应激性溃疡预防,纳入有创通气患者)中前瞻性记录知情同意过程,共5024例患者或替代决策者被接触。总体同意率85.0%(范围27.3%-100%)。52.5%采用事先知情同意,其中26.4%拒绝;47.5%采用延迟知情同意,最终仅2.4%拒绝。多水平logistic回归显示,延迟同意模式(OR 16.56)、与患者本人知情同意(OR 2.67)及疫情期间或疫情后同意(OR 2.01/2.26)与更高同意率独立相关,而ICU规模、研究经验等中心特征无关。
要点
- 在5024例被接触者中,总体知情同意率为85.0%,各中心范围27.3%-100%。
- 延迟知情同意模式与更高同意率独立相关(OR 16.56;95%CI 11.50-23.84),事先同意模式中26.4%拒绝。
- 与患者本人进行知情同意比与替代决策者同意率更高(OR 2.67;95%CI 1.63-4.37)。
- 疫情期间(OR 2.01;95%CI 1.30-3.11)及疫情后(OR 2.26;95%CI 1.34-3.80)同意率高于疫情前。
- ICU规模、ICU研究经验或研究协调员经验与同意率无独立关联。
适用人群与场景
- 参加应激性溃疡预防国际随机试验的有创通气患者或其替代决策者,共5024例被接触者。
- 涉及急诊/ICU场景中需要知情同意的危重症研究参与者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 知情同意模式分为事先知情同意(a priori)和延迟知情同意(deferred,即同意继续)。
- 由研究协调员前瞻性记录同意模式、请求同意者(研究协调员、站点研究者、ICU医生)、提供或拒绝同意者(患者、替代决策者、其他)、获取方式(面对面或电话)及拒绝原因。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:国际随机试验中的前瞻性知情同意过程观察分析,共5024例患者或替代决策者被接触。
- 总体同意率85.0%(范围27.3%-100%);事先同意模式占52.5%,其中26.4%拒绝;延迟同意模式占47.5%,最终2.4%拒绝。
- 首次知情同意接触中,80.2%与替代决策者进行,19.6%与患者本人,0.2%与其他人员。
- 多水平logistic回归:延迟同意模式OR 16.56(95%CI 11.50-23.84)、与患者本人同意OR 2.67(95%CI 1.63-4.37)、疫情期间OR 2.01(95%CI 1.30-3.11)、疫情后OR 2.26(95%CI 1.34-3.80)与更高同意率独立相关。
- 同意率与中心特征(ICU规模、ICU研究经验、研究协调员经验)无独立关联。
证据类型、等级与局限
- 证据类型:基于国际随机试验的前瞻性观察性分析(知情同意过程记录)。
- 局限:原文未明确提及证据等级;为观察性分析,同意模式非随机分配,可能存在混杂。
对床旁实践的改变
- 在ICU研究中,延迟知情同意模式可能提高同意率,但需注意该模式适用于伦理委员会批准且符合当地法规的研究场景。
- 与患者本人进行知情同意可能比仅与替代决策者沟通获得更高同意率,但需评估患者决策能力。
- 中心特征(ICU规模、研究经验)不预测同意率,不能据此预设同意难度。
- 常见陷阱:延迟知情同意最终拒绝率虽低(2.4%),仍需按方案完成后续知情同意或撤回程序。
指南或共识出处
- Crit Care Med
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Research examining informed consent in critical care studies is limited. The objective of this study was to describe the patterns and predictors of consent.
DESIGN: Research coordinators prospectively documented each consent encounter including consent model (a priori or deferred, also known as consent to continue), who requested consent (research coordinator, site investigator, and ICU physician), who provided or declined consent (patient, substitute decision-maker [SDM], and other), the method to obtain consent (in-person or via telephone), and reasons for consent decline, if applicable. Research coordinators retrospectively reported center characteristics. Using multilevel logistic regression, we evaluated the association of consent provision with characteristics of the consent encounter and participating center.
SETTING: International randomized trial of stress ulcer prophylaxis for invasively ventilated patients.
MEASUREMENTS AND MAIN RESULTS: Among 5024 patients or SDMs approached for consent, the consent rate was 85.0% (ranging from 27.3% to 100%). In 2638 patients (52.5%), an a priori approach was used, and of these, 696 patients (26.4%) declined. The remaining 2386 participants (47.5%) were enrolled by deferred consent, of whom 58 participants (2.4%) ultimately declined. Among first consent encounters, 80.2% were with SDMs, 19.6% with patients, and 0.2% with others. Higher consent rates were independently associated with the deferred consent model (odds ratio [OR], 16.56; 95% CI, 11.50-23.84), consent encounters involving patients (OR, 2.67; 95% CI, 1.63-4.37), and consent encounters during the COVID-19 pandemic (OR, 2.01; 95% CI, 1.30-3.11) or postpandemic period (OR, 2.26; 95% CI, 1.34-3.80) compared with prepandemic. Consent rates were not associated with center characteristics including ICU size, ICU research experience, or research coordinator experience.
CONCLUSIONS: Deferred consent was used as often as a priori consent in this trial. The informed consent rate was associated with the deferred model, consent from patients, and consent encounters during or after the pandemic.
参考来源
- Mehta S, Burns KEA, Zytaruk N, et al. Informed Consent in an International Trial of Stress Ulcer Prophylaxis: Patterns and Predictors. Crit Care Med. 2026. PMID: 42627200. doi:10.1097/CCM.0000000000007314
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。